Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 6Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Nasopharyngeal Carcinoma 2Squamous NSCLC 1Squamous Cell Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Resectable Non-small Cell Lung Cancer 1Radiation Pneumonitis 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1MSI-H 1Lung Neoplasms 1HER2+ Breast Cancer 1Gastrointestinal Diseases 1Esophageal Diseases 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Advanced Non-squamous Non-Small-Cell Lung Cancer 1

Interventions

Paclitaxel 2Fluorouracil 2Cisplatin 2zalutumumab 1sintilimab 1pembrolizumab 1Radiotherapy 1Neoadjuvant Therapy 1Mitomycins 1Mitomycin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms, Squamous Cell × sintilimab × Clear all
NCT03748134 2023-10-24

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Completed
746 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡